Last reviewed · How we verify

NCT02463786: INTERACTinHF

Improving Knowledge To Efficaciously RAise Level of Contemporary Treatment in Heart Failure (

Completed Last updated 21 August 2018
What this trial tests

trial testing No intervention in Chronic Heart Failure in 200 participants. Completed in 30 June 2017.

Timeline
1 July 2012
Primary endpoint
30 June 2017
30 June 2017

Quick facts

Lead sponsorMaastricht University Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date1 July 2012
Primary completion30 June 2017
Estimated completion30 June 2017
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Maastricht University Medical Center

Who can join

18 and older, any sex, with Chronic Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Heart failure (HF) remains to have a poor outcome. Even though recent advances in HF led to a reduction of morbidity and mortality, improvement in outcome is much less than expected based on large randomized trials. Various reasons may be responsible, such as complexity of disease and comorbidities, inadequate diagnosis and inappropriate treatment. So far, little attention has been paid on patients seen in primary care. Also, HF care mainly focuses on the individual patient-doctor relationship. However, the increasing complexity prevents individual physicians from covering all aspects of care. Consequently, multiple stakeholders are involved, including both general practitioners and specialists. Still, the relative role, the interaction between them and the processes included are hardly defined. These aspects may not only be relevant for patient care, but also for the setup of health care systems. Whereas multidisciplinary team should resemble a seamless system across primary and hospital care, there is a scarcity of research considering how these disease management programs perform, in what form they should be offered, and what care and support patients and caregivers would benefit most.The INTERACT-in HF (Improving kNowldege Transfer to Efficaciously RAise level of Contemporary Treatment in Heart Failure) study is set up to determine and assess relevant factors of the quality of HF care. The study evaluates processes of HF care, role of relevant care givers and interactions between them. It collects data from individual patients to assess characteristics and management of contemporary HF patients. This is performed in different countries (the Netherlands, Belgium and Germany) to analyze decision making with respect to diagnostics and treatment.Cross-sectional mixed-methods are used. Patients and their caregivers are interviewed. The patient is the central starting point. Then, the treating GP, cardiologist and HF nurse are interviewed. In parallel, retrospective data based on records from these patients are reviewed to verify data from interviews and to determine characteristics of them. Retrospective data of additional patients are collected to complete the picture of the current situation. These data will be used to define bottlenecks that prevent best clinical practice to be used in daily care at all levels, comparing practice in different countries.Thus, the proposal aims to better understand HF care, which will lead to a better care and finally to improved outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Chronic Heart Failure

Currently open trials in the same condition.

Other Maastricht University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02463786.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing